In2Bones
Game-Changing Surgical Innovations

‘Underserved’—is a word that Jon Simon, In2Bones’ Senior VP of Marketing, uses to outline the current state of the extremity market, and the need for equipping surgeons with innovative products and services. As someone whose career has unfolded since the early days of the extremities industry, such ingenious insight, market observation, and problem solving is part of day-to-day operations at In2Bones. As Simon puts it, “The market is hungry for new products and simpler streamlined instruments. Innovation is key to improved patient care, cost containment, and the growth of our industry.” In response to these needs and governed by a mission to spark transformation in the extremities market, prominent experts from the orthopedic industry laid the cornerstone of In2Bones—a rapid growth company that takes a global approach to advance the science and technology of extremity implants.

In2Bones is an outcome of ‘a global need for innovation’ and ‘two decades of domain expertise’ in the extremities market. In an effort to manage the economics, time, and efficiency aspects of medical devices and operating room (OR) instruments, In2Bones is equipping surgeons and hospitals with sterile packaged implants and single-use instrument sets. The company strives to achieve its product expansion goals with leading-edge implant designs, and advanced materials like polyether ether ketone (PEEK), bioactive glass, cortical allograft fixation, and Type II anodized titanium.

With technology advances being the engine of growth for both large and small companies, In2Bones is ahead of its time in a marketplace that is replete with many vendors offering numerous solutions that claim to be ‘original.’ “Many of the large orthopedic companies have a history of building their extremity portfolios and divisions based on their trauma products and platforms. The products developed by large suppliers can, at times, be outdated even prior to launch, based on their long product development lead time,” reveals Simon.

"In2Bones not only replaces the devices surgeons have used for years, but also develops state-of-the-art extremities implants and instrumentation that provide new advantages for surgeons, patients, and hospitals"

That’s not the case at In2Bones. The company finds its competitive advantage in having a close relationship with thought leaders in the extremity space, together with internal market knowledge that allows it to pioneer and develop products at a much quicker pace. In2Bones is making their unique voice heard and is bringing its distinctive perspective to continue to expand the market. From the outset, In2Bones has been driven by originality, developing product designs— including fully pre-sterilized devices and single-use surgical instrument sets—that directly answer the needs of today’s healthcare practitioners and organizations, providing a range of benefits including improved efficiencies, surgical outcomes, and overall patient care.

How They Are Doing It: The In2Bones Innovation

“In2Bones not only replaces the devices surgeons have used for years, but also develops state-of-the-art extremities implants and instrumentation that provide new advantages for surgeons, patients, and hospitals,” says Simon. The In2Bones team brings to bear its experience with a broad variety of materials, including metallic alloys, biologics, and elastomers, to develop products across multiple platforms and indications.

In2Bones ensures surgical instruments are pre-sterilized, opened and used for the first time, and discarded for recycling after the first use. Our fixation implants and calibrated instruments are guaranteed to only touch one patient, ever

“Implant manufacturer representatives usually bring in surgical trays with instruments, fixation devices, drill bits, and screws that have gone through countless re-sterilization processes.” explains Alan Taylor, President and CEO of In2Bones.“There are known risks associated with re-processing implants and instruments, such as contaminants entering the OR particle wear and fatigue, and corrosion of metal from the cleaning and sterilization process. In2Bones ensures such surgical instruments are pre-sterilized, opened and used for the first time, and discarded for recycling after the first use. Our fixation implants and calibrated instruments are guaranteed to only touch one patient, ever.” Working with single-use products eliminates the painstaking process of sterilizing instruments prior to every surgery, as well as the risk of contamination that comes with it. In addition, single-use disposable instruments can save around $400 to $750 per case by reducing hospital labor and sterilization costs. Disposable instruments can also lower upfront and replacement costs, stand up to the rigors of surgery, help prevent expensive surgical site infections, and reduce liability risks. They also help drastically reduce OR delays by eliminating the hour-long reprocessing of instruments, according to a study conducted with members of the Association of periOperative Registered Nurses (AORN).

An example of the company’s emphasis on designs that improve surgical technique and patient outcomes is the CoLag^® Screw – one of the most significant screw design innovations in 25 years. This screw has a unique thread and low-profile head design, which allows for increased stability and 77 percent more compression than a typical headless screw. The vision behind this technology was to innovate on an existing commodity product. Several of In2Bones’ surgeon clients leverage this added stability to have multiple phases of compression across a fracture site.

Another example of product innovation was initiated by the need to treat professional athletes with slow-to-heal fifth metatarsal “Jones Fractures,” In2Bones has devised a 5MS^® Fracture Plating System that uses interchangeable 2.4 and 2.7 screws for all plate types, with the exception of the large plantar plate, which is compatible with 3.0 and 3.5 screws only. The anatomically contoured Plantar Plates are designed for increased biomechanical strength, resisting rotational instability and plantar-lateral gapping at the tension side of the fracture.

Indications include nonunions from previous IM screw fixation, curved 5th metatarsal anatomy, and sclerotic nonunions. In2Bones fueled these innovations by working closely with leading surgeons and creating specific products to solve many of their unmet needs.

Creating Better Outcomes

With its goal to expand the surgical implants and instruments market with innovative products, In2Bones carried out studies with PEEK material to find applications where it can serve as a better alternative to a typical metal implant, leading to the creation of radio-transparent fixation devices. “The result was a new implant that has a modulus of elasticity closer to cortical and cancellous bone, which can help increase osteosynthesis without any of the drawbacks of metal, including issues related to cold-welding and allergic reactions,” explains Simon. In2Bones’ fixation devices can also be used for patients with metal allergies or those looking for an alternative to metal implants.



In2Bones’ PEEK-based innovation has been accepted as an alternative to a traditional metal implant by leading surgeons across the globe. The company has a broad a line of PEEK implants including the OS2^® VP Staple and the DuaFit^® PIP that allow surgeons to use more advanced implants instead of a minimal fixation or a K-wire. In addition to being single-use and on-demand, the OS2 VP Staple’s compression on release design and PEEK construction offer constant and reproducible compression and is widely used for its biocompatibility and mechanical qualities.

Innovation Is the Name of the Game

Owing to its unparalleled surgical inventions and successful market penetration, In2Bones has delivered an impressive, greater than 100 percent year-over-year (YOY) growth rate since its inception in 2014. The company has a global reach, catering to over 25 countries around the world, and is constantly delivering game-changing product innovations. With a fast product development cycle, In2Bones is well-positioned to quickly respond to the market needs and capitalize on current and future market trends. Compared to its competitors’ often slow release of one product per year, the company stands a mile ahead, launching more than 10 new products in the last two years, along with additional products due for FDA approval and release during the remainder of 2018. With rich business knowledge, long-standing relationships, and a successful track record, Taylor and his team will continue to expand its ankle-hindfoot product pipeline, along with identifying unmet needs and aggressively creating unique solutions to improve surgical outcomes and patient care. That said, there are two aspects that In2Bones is driven to bring to the forefront while leaving no stone unturned: innovation and unprecedented knowledge.